(UroToday.com) Lenvatinib + pembrolizumab improved PFS, OS, and objective response rate versus sunitinib in the first-line treatment of patients with advanced RCC, while lenvatinib + everolimus improved PFS and objective response rate versus sunitinib.1 The safety profiles of both combinations were consistent with each drug’s known profile and generally manageable, as needed, through dose modifications. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Robert Motzer and colleagues presented results of a secondary objective of the CLEAR trial comparing the impact of lenvatinib + pembrolizumab or everolimus versus sunitinib, on HRQoL.